Department of Urology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Eur Urol. 2010 Jan;57(1):86-93. doi: 10.1016/j.eururo.2009.03.057. Epub 2009 Mar 31.
For bladder cancer (BCa) patients undergoing bladder-sparing treatments, molecular markers may aid in accurately predicting progression to muscle invasion and recurrence. Hyaluronic acid (HA) is a glycosaminoglycan that promotes tumor metastasis. Hyaluronoglucosaminidase 1 (HYAL-1)-type hyaluronidase (HAase) promotes tumor growth, invasion, and angiogenesis. Urinary HA and HAase levels are diagnostic markers for BCa.
We evaluated whether HA and HYAL-1 can predict progression to muscle invasion and recurrence among patients with non-muscle-invasive BCa.
DESIGN, SETTING, AND PARTICIPANTS: : Based on tissue availability, tissue microarrays were prepared from a cohort of 178 BCa specimens (144 non-muscle invasive, 34 muscle invasive). Follow-up information was available on 111 patients with non-muscle-invasive BCa (mean follow-up: 69.5 mo); 58 patients recurred and 25 progressed to muscle invasion (mean time to progress: 22.3 mo).
HA and HYAL-1 expression was evaluated by immunohistochemistry and graded for intensity and area of staining. Association of HA and HYAL-1 staining with BCa recurrence and muscle invasion was evaluated by univariate and multivariate models.
HA and HYAL-1 expression correlated with tumor grade, stage, and multifocality (p<0.05). In non-muscle-invasive BCa specimens, HYAL-1 staining was higher (234.3+/-52.2; 200.6+/-61.4) if patients experienced progression to muscle invasion or recurrence when compared with no progression or recurrence (164.1+/-48.2; 172.1+/-57; p<0.001). HA staining correlated with muscle invasion (p<0.001). In univariate analysis, age (p=0.014), multifocality (p=0.023), and HYAL-1 staining (p<0.001) correlated with muscle invasion, whereas only HYAL-1 correlated with recurrence (p=0.013). In multivariate analysis, HYAL-1 significantly associated with muscle invasion (p<0.001; 76.8% accuracy) and recurrence (p=0.01; 67.8% accuracy).
HYAL-1 is a potential prognostic marker for predicting progression to muscle invasion and recurrence.
对于接受保膀胱治疗的膀胱癌(BCa)患者,分子标志物可能有助于准确预测向肌肉浸润和复发的进展。透明质酸(HA)是一种促进肿瘤转移的糖胺聚糖。透明质酸酶 1(HYAL-1)型透明质酸酶(HAase)促进肿瘤生长、侵袭和血管生成。尿 HA 和 HAase 水平是 BCa 的诊断标志物。
我们评估 HA 和 HYAL-1 是否可以预测非肌肉浸润性 BCa 患者向肌肉浸润和复发的进展。
设计、地点和参与者:根据组织可用性,从 178 例 BCa 标本(144 例非肌肉浸润性,34 例肌肉浸润性)中制备组织微阵列。111 例非肌肉浸润性 BCa 患者可获得随访信息(平均随访时间:69.5 个月);58 例患者复发,25 例进展为肌肉浸润(平均进展时间:22.3 个月)。
通过免疫组织化学评估 HA 和 HYAL-1 的表达,并对染色强度和面积进行分级。通过单变量和多变量模型评估 HA 和 HYAL-1 染色与 BCa 复发和肌肉浸润的关系。
HA 和 HYAL-1 的表达与肿瘤分级、分期和多灶性相关(p<0.05)。在非肌肉浸润性 BCa 标本中,如果患者进展为肌肉浸润或复发,与无进展或复发相比,HYAL-1 染色更高(234.3+/-52.2;200.6+/-61.4)(p<0.001)。HA 染色与肌肉浸润相关(p<0.001)。在单变量分析中,年龄(p=0.014)、多灶性(p=0.023)和 HYAL-1 染色(p<0.001)与肌肉浸润相关,而只有 HYAL-1 与复发相关(p=0.013)。在多变量分析中,HYAL-1 与肌肉浸润显著相关(p<0.001;76.8%准确性)和复发(p=0.01;67.8%准确性)。
HYAL-1 是预测向肌肉浸润和复发进展的潜在预后标志物。